Treasury’s draft outbound investment rules would sharply limit US deals for Chinese drug and biotech assets, opening a 45-day ...
AbbVie’s IL-1α and IL-1β inhibitor lutikizumab improved patient response rates after 16 weeks by a statistically significant ...
Sanofi breaks ground on a Frankfurt insulin plant, FDA warns Baxter over cephalosporin contamination, and radiopharma players ...
Roche touts 88% Phase 3 success rate as it culls afimkibart’s AD trial and seven early assets ahead of giredestrant launch.
Redesign Health merges with Sheba Medical Center’s ARC Global in a roughly $2B deal and plans to acquire advisory firm AVIA.
Roche’s Teresa Graham says patients are clamoring for breast cancer pill giredestrant as two US approval decisions near.
Arbutus' AB-101 hold lifted; GSK drops HBV drug; Ultomiris approved for IgAN; Biohaven resubmits SCA app; Arcus raises $250M; ...
FDA weighs evidence standards for AI medical devices like prescription bots. AMA opposes upfront uncertainty; ATA Action supports post-market monitoring. UpDoc, AMA, and others back risk-based ...
Roivant's brepocitinib (Lisraya) succeeded in two non-infectious uveitis trials, with plans to file for approval in H1 2027.
FDA approves GSK and Ionis’ hepatitis B drug Hibsago early, but a boxed warning and weekly lab monitoring could slow uptake.
CDMO Adare Pharma Solutions is closing a facility in Philadelphia and letting go of 137 workers, a little over a year after relocating its headquarters to Pennsylvania. The ...
Deborah Waterhouse will take on the CEO post at CSL on Feb. 1 as the Australian pharma company attempts a turnaround after ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results